Jan. 21 at 10:40 PM
$LAB “As we look to 2026, the sale of SomaLogic to Illumina remains on track to close in the first half of the year. At close, we expect to have approximately
$550 million in cash and a base business on its way to positive adjusted EBITDA — a combination that creates real strategic flexibility. With an experienced team, a simplified footprint and substantial cash, we are well positioned to pursue disciplined M&A as we work to build a diversified leader in life sciences."
